Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
Natacha C Villegas, Wen-Shin Lee Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USACorrespondence: Natacha C VillegasDepartment of Ophthalmology, Stanford University, Medical Center, 2452 Watson Court, Palo Alto, CA, 94303-5353, USATel +1 832 477-3498Email natacha...
Enregistré dans:
Auteurs principaux: | Villegas NC, Lee WS |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3cbfed0c33da4bf6a7fda5d577a9e67a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
par: Dasso L, et autres
Publié: (2018) -
Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
par: Lerner SF, et autres
Publié: (2019) -
Topical Medication Therapy for Glaucoma and Ocular Hypertension
par: Tao Wang, et autres
Publié: (2021) -
Glaucoma therapy: preservative-free for all?
par: Thygesen J
Publié: (2018) -
Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
par: Muñoz Negrete FJ, et autres
Publié: (2017)